Gastrointestinal Neoplasms  >>  Zykadia (ceritinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
NCT02638909: Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Terminated
2
4
US
ceritinib, Zykadia
Criterium, Inc., University of Colorado, Denver, Novartis
Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
03/18
03/18

Download Options